Gallium-68 Labeled Pentixafor PET/CT in Adrenal Masses

Adrenal Mass Clinical Trial

Official title:

Gallium-68 Labeled Pentixafor PET/CT in the Diagnosis and Characterization of Adrenal Masses

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04859959
• Other study ID #: PenAM
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: July 1, 2018
• Est. completion date: December 1, 2022

Study information

• Verified date: July 2020
• Source: Peking Union Medical College Hospital
• Contact: Jie Ding, MD
• Phone: +86 17810259215
• Email: 707462902[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The CXC chemokine receptor type 4 (CXCR4), which is a G protein-coupled receptor expressed on the surface of the cell membrane, contributes to the development and progression of malignancies and functional endocrine disorders. CXCR4 expression has been reported to be upregulated in aldosterone-producing adenomas and cortisol-producing adenomas; however, its expression is almost negligible in non-functioning adrenal adenomas. Besides, CXCR4 is also hardly expressed by the tumor cells in paragangliomas. 68Ga-pentixafor, a CXCR4-specific PET tracer, may therefore be effective for the evaluation of the functional lateralization of adrenal lesion and identification of functional adrenocortical adenomas. In this pilot study, we aimed to develop 68Ga-pentixafor PET/CT as a noninvasive test for the recognition of functional adrenocortical lesions and to help guide the management of patients with suspicious adrenal masses.

Description:

Identifying the functional distinctions between adrenal nodules remains challenging. It is imperative to employ the least invasive approach for the functional evaluation of adrenal masses (e.g., adrenal venous sampling) without compromising efficacy. The conventional functional diagnosis protocol of adrenal masses is based on a combination of clinical symptoms, the presence of adrenal hormonal disorders, and radiographic features. However, the clinical manifestations of endocrine diseases are diverse, and a lack of uniformity in diagnostic protocols and assay methods for determining hormonal activation in adrenal disorders results in a significant variability in measurements. Besides, conventional imaging provides information of the morphology of a lesion, but not its functional status. Thus, an effective and non-invasive workup is needed for the characterization of adrenal masses and their therapeutic management.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: December 1, 2022
• Est. primary completion date: July 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Written informed consent.

• Patients with adrenal diseases.

• A diagnostic computed tomography (CT) or magnetic resonance imaging (MRI) of the adrenal region within the previous 6 months prior to dosing day is available

Exclusion Criteria:

• Pregnant or breast-feeding women.

• Prior or planned administration of a radiopharmaceutical within 8 half-lives of the radionuclide used on such radiopharmaceutical including at any time during the current study.

• Any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude

Related Conditions & MeSH terms

• Adrenal Mass

Intervention

Diagnostic Test:
• Gallium-68 Pentixafor PET/CT
Intravenous injection of one dosage of 74-222 MBq (2-6 mCi) Gallium-68 Pentixafor. Tracer doses of Gallium-68 Pentixafor will be used to image adrenal lesions by PET/CT.

Locations

Country	Name	City	State
China	Peking Union Medical College Hospital	Peking

Sponsors (1)

Lead Sponsor	Collaborator
Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The diagnosis efficiency	The diagnosis efficiency of functional lateralization and identification of functional adrenocortical adenomas	through study completion, an average of 2 year
Secondary	Standard uptake value (SUV)	Determination of SUV for detected lesions and normal liver and adrenal tissue of 68Ga-Pentixafor	From right after tracer injection to 2-hours post-injection